1.Evaluation of a fluorescent and radiolabeled hybrid somatostatin analogue in vitro and in mice bearing H69 neuroendocrine xenografts.
Santini C1, Kuil J2, Bunschoten A2, Pool SE1, de Blois E1, Ridwan Y1, Essers J1, Bernsen M1, Leeuwen FW2, de Jong M1. J Nucl Med. 2016 Apr 28. pii: jnumed.115.164970. [Epub ahead of print]
In the treatment of neuroendocrine tumors (NET), complete surgical removal of malignancy is generally desirable, as it offers curative results. Pre-operative guidance with radiolabeled somatostatin analogues, commonly used for NET diagnosis and pre-operative planning, is limited by its low resolution, with the risk that tumor margins and small metastases will be incompletely resected with subsequent recurrence. A single hybrid probe combining radiotracer and optical dye would enable high-resolution optical guidance, also during surgery. In the current study, the hybrid labeled somatostatin analogue Cy5-DTPA-Tyr3-octreotate was synthesized and evaluated for its ability to specifically trace NET cells in vitro and in an animal model. The performance of the hybrid tracer was compared to that of octreotate with only radiolabel or only optical label.
2.Effect of Somatostatin, Ulinastatin and Gabexate on the Treatment of Severe Acute Pancreatitis.
Wang G1, Liu Y2, Zhou SF3, Qiu P4, Xu L4, Wen P4, Wen J4, Xiao X5. Am J Med Sci. 2016 May;351(5):506-12. doi: 10.1016/j.amjms.2016.03.013. Epub 2016 Mar 31.
OBJECTIVE: The objective of this study is to evaluate the efficacy of somatostatin, ulinastatin and gabexate for the treatment of severe acute pancreatitis.